The 2nd International Conference on Drug Discovery & Therapy: Dubai, February 1 - 4, 2010


Poster Presenter

Detection of CTX-M-β Lactamases in Isolated Klebsiella pneumoniae from Selected Hospitals of Tehran
Parviz Owlia*, Zakaria Bameri, Mohsen Chitsaz

Background and Objective: Organisms producing CTX-M β-lactamases are emerging around as a source of resistance to oxyiminocefalosporins such as ceftriaxone and ceftazidime. However, the laboratory detection of these strains is not well defined. In this study, phenotypic assay for screening of extended-spectrum β-lactamases producing strains and molecular assay for the identification of CTX-M β-lactamases genes was developed and used to investigate the prevalence of these enzymes among clinical isolates of Klebsiella pneumoniae in the three general hospitals.

Materials and Methods: Phenotypic detection was used for screening of isolates by agar dilution method. A decrease of =3 doubling dilution in an MIC for either ceftriaxone or ceftazidime tested in combination with 4 mg/L clavulanic acid(prepared from Glasco Smith company) versus its MIC when tested alone, confirmed an ESBL-producing organism. The PCR assay consisted of four primer sets.

Results: In initial screening test, 117 (69%) from 168 clinical isolates were positive and 51 isolates (31%) were negative. From the positive isolates 96 isolates were positive in phenotypic confirmatory test. Using molecular assay, 117 strains potentially producing extended-spectrum-β-lactamases were examined for the presence of CTX-M enzymes: 88 strains (75.2%) were positive for blactx-m group I genes, I strain (0.85%) was positive for blactx-m group
III genes , and 2 strains (1.7%) were positive for blactx-m group IV.

Conclusion: In this study we showed that prevalence of extended-spectrum β-lactamases (ESBLs) are increasing significantly in hospitals of Tehran. In other side we found that the CTX-M group has the most prevalence than other CTX-M groups in hospitals of Tehran.




[Webmaster]   Copyright © 2010 2nd International Conference on Drug Design & Therapy